ResMed wins sales ban against APEX in Germany
29 July, 2014 by Dylan Bushell-EmblingA German court has issued an injunction prohibiting Taiwan's APEX Medical from local sales of two face masks found to infringe on ResMed (ASX:RMD) patents.
Wikibomb to boost online role models for women scientists
29 July, 2014The Australian Academy of Science is holding the Women of Science Wikibomb as part of the coming National Science Week activities, and interested individuals are invited to help create and improve the Wikipedia pages of Australian female scientists.
Report shows Employee Share Schemes could boost economy
24 July, 2014A new report shows that a reversal of the 2009 Employee Share Scheme (ESS) laws would potentially boost the Australian economy by more than $1.4 billion in the long term.
Win for ResMed as ITC upholds import ban
22 July, 2014 by Dylan Bushell-EmblingThe US ITC has upheld an import ban on a device sold by Taiwan's APEX found to infringe on ResMed patents, even after a redesign.
PolyNovo gets CE Mark for NovoPore dressing
22 July, 2014 by Dylan Bushell-EmblingCalazada's (ASX:CZD) PolyNovo now has approval to market its NovoPore TNP dressing in the majority of its addressable market, after securing approvals in Europe.
Perth's Orthocell raises $8m in oversubscribed IPO
22 July, 2014 by Dylan Bushell-EmblingOrthocell has completed an IPO, raising $8m to help market and prepare approvals for its regenerative medicine products, while paving the way for an ASX listing in August.
New one-stop portal for government's business support
22 July, 2014As part of changes to business support made in the May federal Budget, the Department of Industry's services will be accessed via a new one-stop web portal called the Single Business Service.
The state of innovation
21 July, 2014The Global Innovation Index 2014 has ranked Australia 17th out of 143 economies for having a well-linked innovation ecosystem.
Starpharma close to first major revenues
21 July, 2014 by Dylan Bushell-EmblingAnsell has secured Australian certification for a line of condoms coated with Starpharma's (ASX:SPL) VivaGel, and aims to launch a line of products in the next few months.
Annual global biotech report released
17 July, 2014EY's annual report on the global biotechnology industry shows the industry rebounded strongly in 2013, with public companies achieving double-digit revenue growth and a sharp rise in funds raised. Product successes have boosted revenues, drawn investors and motivated large companies to invest strongly in R&D.
Calzada announces organisational revamp
16 July, 2014 by Dylan Bushell-EmblingCalzada (ASX:CZD) plans an organisational restructuring involving appointing a managing director for its PolyNovo business and recruiting new clinical, regulatory, commercial and manufacturing talent.
Personalised medicine start-up DoseMe raises $500K
15 July, 2014 by Dylan Bushell-EmblingBrisbane-based start-up DoseMe has picked up $500K in investment funding to expand the market reach and supported medications for its personalised dosage calculation software.
New council of international biotech associations formed
15 July, 2014An international confederation of biotechnology trade associations, with membership across six continents, has created the International Council of Biotechnology Associations (ICBA), with the expressed purpose of advocating for public policies that support the global growth of the innovative biotechnology industry.
Phosphagenics raising $19.3m for TPM trials
14 July, 2014 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has launched a $19.3m capital raising to fund trials for its two TPM/opioid patches as the company ramps up its commercialisation efforts.
FDA approves StarPharma's VivaGel trial design
14 July, 2014 by Dylan Bushell-EmblingThe US FDA has granted Starpharma (ASX:SPL) a Special Protocol Assessment for the design of two phase III trials of VivaGel for the prevention of recurrent bacterial vaginosis.
